Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen

Sattva S. Neelapu, Sivasubramanian Baskar, Barry L. Gause, Carol Kobrin, Thelma M. Watson, Andrea Robin Frye, Robin Pennington, Linda Harvey, Elaine S. Jaffe, Richard J. Robb, Mircea C. Popescu, Larry W. Kwak

Research output: Contribution to journalArticle

Abstract

Purpose: The idiotype (Id) of the immunoglobulin on a given B-cell malignancy is a clonal marker that can serve as a tumor-specific antigen. We developed a novel vaccine formulation by incorporating Id protein with liposomal lymphokine that was more potent than a prototype, carrier-conjugated Id protein vaccine in preclinical studies. In the present study, we evaluated the safety and immunogenicity of this vaccine in follicular lymphoma patients. Experimental Design: Ten patients with advanced-stage follicular lymphoma were treated with five doses of this second generation vaccine after chemotherapy-induced clinical remission. All patients were evaluated for cellular and humoral immune responses. Results: Autologous tumor and Id-specific type I cytokine responses were induced by vaccination in 10 and 9 patients, respectively. Antitumor immune responses were mediated by both CD4+ and CD8+ T cells, were Iranian lymphocyte antigen class I and II associated, and persisted 18 months beyond the completion of vaccination. Specific anti-Id antibody responses were detected in four patients. After a median follow-up of 50 months, 6 of the 10 patients remain in continuous first complete remission. Conclusions: This first clinical report of a liposomal cancer vaccine demonstrates that liposomal delivery is safe, induces sustained tumor-specific CD4+ and CD8 + T-cell responses in lymphoma patients, and may serve as a model for vaccine development against other human cancers and infectious pathogens.

Original languageEnglish (US)
Pages (from-to)8309-8317
Number of pages9
JournalClinical Cancer Research
Volume10
Issue number24
DOIs
StatePublished - Dec 15 2004
Externally publishedYes

Fingerprint

Lymphoma
T-Lymphocytes
Antigens
Vaccines
Neoplasms
Follicular Lymphoma
Immunoglobulin Idiotypes
Vaccination
Histocompatibility Antigens Class I
Cancer Vaccines
Lymphokines
Histocompatibility Antigens Class II
Neoplasm Antigens
Humoral Immunity
Cellular Immunity
Antibody Formation
Anti-Idiotypic Antibodies
Proteins
B-Lymphocytes
Research Design

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen. / Neelapu, Sattva S.; Baskar, Sivasubramanian; Gause, Barry L.; Kobrin, Carol; Watson, Thelma M.; Frye, Andrea Robin; Pennington, Robin; Harvey, Linda; Jaffe, Elaine S.; Robb, Richard J.; Popescu, Mircea C.; Kwak, Larry W.

In: Clinical Cancer Research, Vol. 10, No. 24, 15.12.2004, p. 8309-8317.

Research output: Contribution to journalArticle

Neelapu, SS, Baskar, S, Gause, BL, Kobrin, C, Watson, TM, Frye, AR, Pennington, R, Harvey, L, Jaffe, ES, Robb, RJ, Popescu, MC & Kwak, LW 2004, 'Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen', Clinical Cancer Research, vol. 10, no. 24, pp. 8309-8317. https://doi.org/10.1158/1078-0432.CCR-04-1071
Neelapu, Sattva S. ; Baskar, Sivasubramanian ; Gause, Barry L. ; Kobrin, Carol ; Watson, Thelma M. ; Frye, Andrea Robin ; Pennington, Robin ; Harvey, Linda ; Jaffe, Elaine S. ; Robb, Richard J. ; Popescu, Mircea C. ; Kwak, Larry W. / Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen. In: Clinical Cancer Research. 2004 ; Vol. 10, No. 24. pp. 8309-8317.
@article{3af9ce54f53e4d2ba05ec08c61343add,
title = "Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen",
abstract = "Purpose: The idiotype (Id) of the immunoglobulin on a given B-cell malignancy is a clonal marker that can serve as a tumor-specific antigen. We developed a novel vaccine formulation by incorporating Id protein with liposomal lymphokine that was more potent than a prototype, carrier-conjugated Id protein vaccine in preclinical studies. In the present study, we evaluated the safety and immunogenicity of this vaccine in follicular lymphoma patients. Experimental Design: Ten patients with advanced-stage follicular lymphoma were treated with five doses of this second generation vaccine after chemotherapy-induced clinical remission. All patients were evaluated for cellular and humoral immune responses. Results: Autologous tumor and Id-specific type I cytokine responses were induced by vaccination in 10 and 9 patients, respectively. Antitumor immune responses were mediated by both CD4+ and CD8+ T cells, were Iranian lymphocyte antigen class I and II associated, and persisted 18 months beyond the completion of vaccination. Specific anti-Id antibody responses were detected in four patients. After a median follow-up of 50 months, 6 of the 10 patients remain in continuous first complete remission. Conclusions: This first clinical report of a liposomal cancer vaccine demonstrates that liposomal delivery is safe, induces sustained tumor-specific CD4+ and CD8 + T-cell responses in lymphoma patients, and may serve as a model for vaccine development against other human cancers and infectious pathogens.",
author = "Neelapu, {Sattva S.} and Sivasubramanian Baskar and Gause, {Barry L.} and Carol Kobrin and Watson, {Thelma M.} and Frye, {Andrea Robin} and Robin Pennington and Linda Harvey and Jaffe, {Elaine S.} and Robb, {Richard J.} and Popescu, {Mircea C.} and Kwak, {Larry W.}",
year = "2004",
month = "12",
day = "15",
doi = "10.1158/1078-0432.CCR-04-1071",
language = "English (US)",
volume = "10",
pages = "8309--8317",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "24",

}

TY - JOUR

T1 - Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen

AU - Neelapu, Sattva S.

AU - Baskar, Sivasubramanian

AU - Gause, Barry L.

AU - Kobrin, Carol

AU - Watson, Thelma M.

AU - Frye, Andrea Robin

AU - Pennington, Robin

AU - Harvey, Linda

AU - Jaffe, Elaine S.

AU - Robb, Richard J.

AU - Popescu, Mircea C.

AU - Kwak, Larry W.

PY - 2004/12/15

Y1 - 2004/12/15

N2 - Purpose: The idiotype (Id) of the immunoglobulin on a given B-cell malignancy is a clonal marker that can serve as a tumor-specific antigen. We developed a novel vaccine formulation by incorporating Id protein with liposomal lymphokine that was more potent than a prototype, carrier-conjugated Id protein vaccine in preclinical studies. In the present study, we evaluated the safety and immunogenicity of this vaccine in follicular lymphoma patients. Experimental Design: Ten patients with advanced-stage follicular lymphoma were treated with five doses of this second generation vaccine after chemotherapy-induced clinical remission. All patients were evaluated for cellular and humoral immune responses. Results: Autologous tumor and Id-specific type I cytokine responses were induced by vaccination in 10 and 9 patients, respectively. Antitumor immune responses were mediated by both CD4+ and CD8+ T cells, were Iranian lymphocyte antigen class I and II associated, and persisted 18 months beyond the completion of vaccination. Specific anti-Id antibody responses were detected in four patients. After a median follow-up of 50 months, 6 of the 10 patients remain in continuous first complete remission. Conclusions: This first clinical report of a liposomal cancer vaccine demonstrates that liposomal delivery is safe, induces sustained tumor-specific CD4+ and CD8 + T-cell responses in lymphoma patients, and may serve as a model for vaccine development against other human cancers and infectious pathogens.

AB - Purpose: The idiotype (Id) of the immunoglobulin on a given B-cell malignancy is a clonal marker that can serve as a tumor-specific antigen. We developed a novel vaccine formulation by incorporating Id protein with liposomal lymphokine that was more potent than a prototype, carrier-conjugated Id protein vaccine in preclinical studies. In the present study, we evaluated the safety and immunogenicity of this vaccine in follicular lymphoma patients. Experimental Design: Ten patients with advanced-stage follicular lymphoma were treated with five doses of this second generation vaccine after chemotherapy-induced clinical remission. All patients were evaluated for cellular and humoral immune responses. Results: Autologous tumor and Id-specific type I cytokine responses were induced by vaccination in 10 and 9 patients, respectively. Antitumor immune responses were mediated by both CD4+ and CD8+ T cells, were Iranian lymphocyte antigen class I and II associated, and persisted 18 months beyond the completion of vaccination. Specific anti-Id antibody responses were detected in four patients. After a median follow-up of 50 months, 6 of the 10 patients remain in continuous first complete remission. Conclusions: This first clinical report of a liposomal cancer vaccine demonstrates that liposomal delivery is safe, induces sustained tumor-specific CD4+ and CD8 + T-cell responses in lymphoma patients, and may serve as a model for vaccine development against other human cancers and infectious pathogens.

UR - http://www.scopus.com/inward/record.url?scp=19944428027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944428027&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-04-1071

DO - 10.1158/1078-0432.CCR-04-1071

M3 - Article

C2 - 15623607

AN - SCOPUS:19944428027

VL - 10

SP - 8309

EP - 8317

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 24

ER -